Ignite Creation Date:
2025-12-25 @ 1:03 AM
Ignite Modification Date:
2026-01-03 @ 9:32 AM
Study NCT ID:
NCT01614093
Status:
COMPLETED
Last Update Posted:
2019-08-28
First Post:
2012-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Sponsor:
University of Maryland, Baltimore
Organization:
Study Overview
Official Title:
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report) compared to placebo. If this single dose pilot paradigm shows an increase in satiety, it may be tested in follow-up studies as a prevention or treatment for weight gain and overeating in people with schizophrenia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: